Transplant outcomes
| . | 30 days . | 100 days . | 1 y . | 4 y . |
|---|---|---|---|---|
| HHV-6 reactivation (CI) | 46% ± 7% | 57% ± 7% | ||
| Clinically relevant HHV-6 infection (CI) | 20% ± 5% | 24% ± 6% | ||
| Grade 2, 3 or 4 aGVHD (CI) | 28% ± 6% | |||
| Grade 3 or 4 aGVHD (CI) | 13% ± 4% | |||
| cGVHD (CI) | 25% ± 6% | 33% ± 6% | ||
| TRM (CI) | 18 % ± 5% | 26% ± 6% | ||
| Relapse (CI) | 26% ± 6% | 32% ± 6% | ||
| OS | 64% ± 6% | 47% ± 7% | ||
| PFS | 56% ± 7% | 42% ± 7% |
| . | 30 days . | 100 days . | 1 y . | 4 y . |
|---|---|---|---|---|
| HHV-6 reactivation (CI) | 46% ± 7% | 57% ± 7% | ||
| Clinically relevant HHV-6 infection (CI) | 20% ± 5% | 24% ± 6% | ||
| Grade 2, 3 or 4 aGVHD (CI) | 28% ± 6% | |||
| Grade 3 or 4 aGVHD (CI) | 13% ± 4% | |||
| cGVHD (CI) | 25% ± 6% | 33% ± 6% | ||
| TRM (CI) | 18 % ± 5% | 26% ± 6% | ||
| Relapse (CI) | 26% ± 6% | 32% ± 6% | ||
| OS | 64% ± 6% | 47% ± 7% | ||
| PFS | 56% ± 7% | 42% ± 7% |
aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease.